Extract from the Register of European Patents

EP About this file: EP0748219

EP0748219 - COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.02.2006
Database last updated on 21.03.2026
Most recent event   Tooltip10.02.2006No opposition filed within time limitpublished on 29.03.2006  [2006/13]
Applicant(s)For all designated states
Sugen, Inc.
515 Galveston Drive
Redwood City, CA 94063 / US
For all designated states
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
46, Jabotinsky Street
Jerusalem 91042 / IL
[N/P]
Former [2005/14]For all designated states
Sugen, Inc.
515 Galveston Drive
Redwood City, CA 94063 / US
For all designated states
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
46, Jabotinsky Street
Jerusalem 91042 / IL
Former [1996/51]For all designated states
Sugen, Inc.
515 Galveston Drive
Redwood City, CA 94063 / US
For all designated states
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
46, Jabotinsky Street, P.O. Box 4279
Jerusalem 91042 / IL
Inventor(s)01 / GAZIT, Aviv
Nof Harim 14
96190 Jerusalem / IL
02 / LEVITZKI, Alexander
9617 Fall Bridge Lane
Patomic, MA 02854 / US
03 / APP, Harald
30 Melrose Court
Hillsborough, CA 94010 / US
04 / TANG, Cho, Peng
827 Camino Ricardo
Moraga, CA 94556 / US
05 / MCMAHON, Gerald, M.
1414 Greenwich Street
San Francisco, CA 94109 / US
[1996/51]
Representative(s)Jaenichen, Hans-Rainer
Vossius & Partner
Postfach 86 07 67
81634 München / DE
[N/P]
Former [1998/17]Jaenichen, Hans-Rainer, Dr.
Vossius & Partner, Postfach 86 07 67
81634 München / DE
Former [1996/51]Durand, Yves Armand Louis
CABINET WEINSTEIN 20, Avenue de Friedland
75008 Paris / FR
Application number, filing date95910239.309.02.1995
[1996/51]
WO1995US01751
Priority number, dateUS1994019382909.02.1994         Original published format: US 193829
[1996/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9521613
Date:17.08.1995
Language:EN
[1995/35]
Type: A1 Application with search report 
No.:EP0748219
Date:18.12.1996
Language:EN
The application published by WIPO in one of the EPO official languages on 17.08.1995 takes the place of the publication of the European patent application.
[1996/51]
Type: B1 Patent specification 
No.:EP0748219
Date:06.04.2005
Language:EN
[2005/14]
Type: B8 Corrected title page of specification 
No.:EP0748219
Date:08.06.2005
[2005/23]
Search report(s)International search report - published on:US17.08.1995
(Supplementary) European search report - dispatched on:EP03.05.1999
ClassificationIPC:A61K31/24, A61K31/42, A61K31/275, A61K31/415, A61K31/495, C07C211/45, C07C255/01, C07D209/18, C07D231/38, C07D241/36, C07C255/41, C07D239/93
[1999/23]
CPC:
C07D487/04 (EP,US); A61K31/235 (EP,US); A61K31/275 (EP,US);
A61K31/277 (EP,US); A61K31/38 (EP,US); A61K31/40 (EP,US);
A61K31/415 (EP,US); A61K31/42 (EP,US); A61K31/495 (EP,US);
A61K31/502 (EP,US); A61K31/505 (EP,US); A61K31/517 (EP,US);
A61K31/535 (EP,US); A61P1/00 (EP); A61P11/00 (EP);
A61P13/02 (EP); A61P15/00 (EP); A61P17/00 (EP);
A61P27/02 (EP); A61P3/08 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P9/00 (EP); C07C229/60 (EP,US);
C07C255/36 (EP,US); C07C255/40 (EP,US); C07C255/41 (EP,US);
C07C255/66 (EP,US); C07C317/46 (EP,US); C07C327/44 (EP,US);
C07D209/18 (EP,US); C07D239/93 (EP,US); C07D239/94 (EP,US);
C07D241/42 (EP,US); C07D241/44 (EP,US); C07K14/71 (EP,US);
C07K16/2863 (EP,US); G01N33/5008 (EP,US); G01N33/5011 (EP,US);
G01N33/502 (EP,US); G01N33/5064 (EP,US); G01N33/5091 (EP,US);
G01N33/6893 (EP,US); A61K38/00 (EP,US); C07K2319/32 (EP,US);
G01N2333/71 (EP,US); G01N2500/04 (EP,US) (-)
Former IPC [1996/51]A61K31/24, A61K31/42, A61K31/275, A61K31/415, A61K31/495, C07C211/45, C07C255/01, C07D209/18, C07D231/38, C07D241/36, C07D265/34
Designated contracting statesDE,   FR,   GB [1996/51]
TitleGerman:VERBINDUNGEN ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT DER VASCULOGENESE UND/ODER ANGIOGENESE IN ZUSAMMENHANG STEHEN.[2005/19]
English:COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS[1996/51]
French:COMPOSES DESTINES AU TRAITEMENT DE TROUBLES ASSOCIES A LA VASCULOGENESE ET/OU A L'ANGIOGENESE[1996/51]
Former [1996/51]VERBINDUNGEN ZUR BEHANDLUNG VON ERKRANKUNGEN DIE MIT DES VASCULOGENESE UND/ODER ANGIOGENESE VERBUNDEN SIND
Entry into regional phase06.09.1996National basic fee paid 
06.09.1996Search fee paid 
06.09.1996Designation fee(s) paid 
06.09.1996Examination fee paid 
Examination procedure01.09.1995Request for preliminary examination filed
International Preliminary Examining Authority: US
06.09.1996Examination requested  [1996/51]
30.11.2000Despatch of a communication from the examining division (Time limit: M06)
11.06.2001Reply to a communication from the examining division
19.12.2001Despatch of a communication from the examining division (Time limit: M06)
02.08.2002Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
14.10.2002Reply to a communication from the examining division
28.03.2003Despatch of a communication from the examining division (Time limit: M04)
31.07.2003Reply to a communication from the examining division
09.07.2004Communication of intention to grant the patent
19.01.2005Fee for grant paid
19.01.2005Fee for publishing/printing paid
Opposition(s)10.01.2006No opposition filed within time limit [2006/13]
Request for further processing for:14.10.2002Request for further processing filed
14.10.2002Full payment received (date of receipt of payment)
Request granted
25.10.2002Decision despatched
Fees paidRenewal fee
24.02.1997Renewal fee patent year 03
19.02.1998Renewal fee patent year 04
08.02.1999Renewal fee patent year 05
10.02.2000Renewal fee patent year 06
05.02.2001Renewal fee patent year 07
04.02.2002Renewal fee patent year 08
30.01.2003Renewal fee patent year 09
30.01.2004Renewal fee patent year 10
08.02.2005Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X] HU59411  
 [A]   J. MED. CHEM., Volume 26, issued 1983, STOUT et al., "Synthesis and Antiarrhythmic and Parasympatholytic Properties of Substituted Phenols. 1. Heteroarylamine Derivatives", pages 808-813. [A]
 [X]   CHEMICAL ABSTRACTS, Volume 117, issued 1990, KOKOSI et al., "Process for Producing Imidazo[5,1-Beta]Quinazolin-9-one Derivatives and Pharmaceutically Acceptable Salts Thereof, as well as Pharmaceutical Compositions Comprising such as Active Ingredient", Abstract No. 212519; & HU,A, 59 411. [X]
 [X]   ANTI-CANCER DRUGS, Volume 5, issued 1994, KAUR et al., "Tyrphostin Induced Growth Inhibition: Correlation with Effect on P210 bcr-abl Autokinase Activity in K562 Chronic Myelogenous Leukemia", pages 213-222. [X]
 [X]   JOURNAL F. PRAKT. CHEM., Volume 329, No. 1, issued 1987, VOGEL et al., "Synthese von 4-Substituierten 1,2,3-Triazolo[1,5-a]-Chinoxalinen", pages 101-107. [X]
 [X]   JOURNAL OF MEDICINAL CHEMISTRY, Volume 36, issued 1993, GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of Alpha-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins", pages 3556-3564. [X]
 [X]   BIOCHEMISTRY, Volume 32, No. 17, issued 1993, OHMICHI et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor", pages 4650-4658. [X]
 [X]   BIOCHIMICA ET BIOPHYSICA ACTA, Volume 935, issued 1988, MIYOSHI et al., "Quantitative Analysis of the Uncoupling Activity of Substituted Phenols with Mitochondria from Flight Muscles of House Flies", pages 312-321. [X]
 [X]   CANADIAN JOURNAL OF CHEMISTRY, Volume 63, issued 1985, MARLIN, "Resonance Raman Study of Phenylhydrazonopropanedinitriles", pages 1840-1844. [X]
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.